Gene · 28882
Papers3,857
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 3,857
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Pantoprazole as a potential repurposed drug targeting the adenosinergic system in esophageal cancer. | Med Chem Res | 2026 | 42789078 | PubTator, text mining | PubMed |
| Guanfacine and HCN channels: bridging neuroinflammation and prefrontal cortex function in autism spectrum disorder. | Front Mol Neurosci | 2026 | 42781299 | PubTator, text mining | PubMed |
| Developmental changes in Ca2+ signaling mediated by A2A adenosine and mGluR5 glutamate receptors in olfactory bulb astrocytes. | Sci Rep | 2026 | 42660969 | PubTator, text mining | PubMed |
| Reprogramming the immunosuppressive microenvironment in glioblastoma: the microglia-MDSC-Treg axis and translational therapeutic strategies. | Front Oncol | 2026 | 42639384 | PubTator, text mining | PubMed |
| Quantifying Heteromer Partitioning Reveals Inflammation-Dependent Redistribution of Microglial Adenosine A2A and Cannabinoid CB2 Receptors. | Glia | 2026 | 42482393 | PubTator, text mining | PubMed |
| Inflammation, oxidative stress and purinergic signaling in pituitary neuroendocrine tumors (PitNETs). | Purinergic Signal | 2026 | 42412139 | PubTator, text mining | PubMed |
| Circulating ATP from hepatic ischemia-reperfusion drives remote cardiac injury via macrophage inflammasome activation. | Pharmacol Res | 2026 | 42309495 | PubTator, text mining | PubMed |
| Computational evaluation of leflunomide and ticagrelor combination targeting the A2A receptor for the management of rheumatoid arthritis. | Pak J Pharm Sci | 2026 | 42262197 | PubTator, text mining | PubMed |
| Adenosine Signaling in Primary and Metastatic Brain Tumors: Immune Suppression, Tumor Progression, and Therapeutic Opportunities. | Mol Neurobiol | 2026 | 42168394 | PubTator, text mining | PubMed |
| Discovery of Potent 1,3-Cyclobutane-Containing Dual A2A/A2B Receptor Antagonists with Low Projected Human Dose for the Treatment of Cancer. | ACS Med Chem Lett | 2026 | 42157841 | PubTator, text mining | PubMed |
| First-in-human study of the dual A2A/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors. | ESMO Open | 2026 | 42102781 | PubTator, text mining | PubMed |
| Mechanistic multiscale modeling identifies putative natural tri-target candidates of MAO-B, LRRK2 and A₂A for Parkinson's disease. | Sci Rep | 2026 | 42086777 | PubTator, text mining | PubMed |
| Discovery of MK-1088 as a Potent A2A/A2B Adenosine Receptor Dual-Antagonist for Cancer Immunotherapy. | J Med Chem | 2026 | 42084562 | PubTator, text mining | PubMed |
| Perineural invasion in head and neck squamous cell carcinoma: Neuro-immune mechanisms driving immunotherapy resistance and emerging therapeutic strategies. | Drug Resist Updat | 2026 | 42019272 | PubTator, text mining | PubMed |
| Sex Differences in Metabolite-Immune Circuits of Neuroinflammation. | Immunol Rev | 2026 | 41803620 | PubTator, text mining | PubMed |
| Habitual coffee consumption poorly correlates with sleep quality and daytime sleepiness: A cross-sectional study. | PLoS One | 2026 | 41801928 | PubTator, text mining | PubMed |
| Immunometabolism in lung cancer - The link between metabolism and immune response. | iScience | 2026 | 41797927 | PubTator, text mining | PubMed |
| Untargeted metabolomics reveals immune-metabolic signatures in established cases of rheumatoid arthritis. | Front Mol Biosci | 2026 | 41777668 | PubTator, text mining | PubMed |
| Latest surface plasmon resonance advances for G protein-coupled receptors. | J Pharm Anal | 2026 | 41767747 | PubTator, text mining | PubMed |
| A2AR as a key target for immune microenvironment remodeling in prostate cancer. | Transl Oncol | 2026 | 41763068 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28882/papers